Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A Single-arm Phase II Trial Investigating the Efficacy and Safety of Zalutumumab in Patients
with Non-Small Cell Lung Cancer who have Progressive Disease after Treatment with Tyrosine
Kinase Inhibitors.